NASDAQ:BIIB

Biogen Stock Forecast, Price & News

$274.04
+1.93 (+0.71 %)
(As of 05/7/2021 05:20 PM ET)
Add
Compare
Today's Range
$270.66
$279.20
50-Day Range
$259.00
$279.75
52-Week Range
$223.25
$363.92
Volume936,119 shs
Average Volume1.20 million shs
Market Capitalization$41.26 billion
P/E Ratio9.07
Dividend YieldN/A
Beta0.53
30 days | 90 days | 365 days | Advanced Chart
Receive BIIB News and Ratings via Email

Sign-up to receive the latest news and ratings for Biogen and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:BIIB
CUSIP09062X10
Phone617-679-2000
Employees9,100
Year Founded1978

Sales & Book Value

Annual Sales$14.38 billion
Cash Flow$38.38 per share
Book Value$73.93 per share

Profitability

Net Income$5.89 billion

Debt

Price-To-Earnings

Miscellaneous

Market Cap$41.26 billion
Next Earnings Date7/28/2021 (Estimated)
OptionableOptionable

Social Links


Headlines

See More Headlines
Biogen logo

About Biogen

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases worldwide. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; and FLIXABI, an infliximab biosimilar referencing REMICADE. In addition, the company offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; and OCREVUS for treating relapsing MS and primary progressive MS; and other anti-CD20 therapies. Further, it develops BIIB061, BIIB091, and BIIB107 for MS and neuroimmunology; Aducanumab, BAN2401, BIIB092, BIIB076, and BIIB080 to treat Alzheimer's disease and dementia; BIIB067, BIIB078, BIIB105, BIIB100, and BIIB110 to treat neuromuscular disorders; BIIB124, BIIB094, BIIB118, BIIB101, and BIIB122 for treating Parkinson's disease and movement disorders; BIIB111 and BIIB112 to treat ophthalmology related diseases; BIIB125 and BIIB104 for treating neuropsychiatry; Dapirolizumab pegol and BIIB059 to treat immunology related diseases; BIIB093 and TMS-007 to treat acute neurology; BIIB074 and BIIB095 for neuropathic pain; and SB11 and SB15 biosimilars, which are under various stages of development. The company offers products through its sales force and marketing groups. It has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Bristol-Myers Squibb Company; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; and Ionis Pharmaceuticals, Inc. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.

MarketRank

Overall MarketRank

1.74 out of 5 stars

Medical Sector

82nd out of 2,041 stocks

Biological Products, Except Diagnostic Industry

9th out of 176 stocks

Analyst Opinion: 2.1Community Rank: 3.0Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 1.9 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











Biogen (NASDAQ:BIIB) Frequently Asked Questions

Is Biogen a buy right now?

30 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Biogen in the last year. There are currently 4 sell ratings, 14 hold ratings and 12 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" Biogen stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in BIIB, but not buy additional shares or sell existing shares.
View analyst ratings for Biogen
or view top-rated stocks.

What stocks does MarketBeat like better than Biogen?

Wall Street analysts have given Biogen a "Hold" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Biogen wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Biogen's next earnings date?

Biogen is scheduled to release its next quarterly earnings announcement on Wednesday, July 28th 2021.
View our earnings forecast for Biogen
.

How were Biogen's earnings last quarter?

Biogen Inc. (NASDAQ:BIIB) posted its quarterly earnings data on Wednesday, April, 21st. The biotechnology company reported $5.34 EPS for the quarter, beating the Thomson Reuters' consensus estimate of $5.06 by $0.28. The biotechnology company had revenue of $2.69 billion for the quarter, compared to analyst estimates of $2.67 billion. Biogen had a net margin of 35.63% and a trailing twelve-month return on equity of 51.00%. Biogen's revenue for the quarter was down 23.8% on a year-over-year basis. During the same quarter last year, the business posted $9.14 earnings per share.
View Biogen's earnings history
.

How has Biogen's stock been impacted by Coronavirus (COVID-19)?

Biogen's stock was trading at $294.25 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, BIIB shares have decreased by 7.0% and is now trading at $273.76.
View which stocks have been most impacted by COVID-19
.

How will Biogen's stock buyback program work?

Biogen announced that its Board of Directors has approved a share repurchase plan on Monday, December 23rd 2019, which permits the company to repurchase $5,000,000,000.00 in shares, according to EventVestor. This repurchase authorization permits the company to purchase shares of its stock through open market purchases. Stock repurchase plans are usually an indication that the company's leadership believes its shares are undervalued.

What guidance has Biogen issued on next quarter's earnings?

Biogen issued an update on its FY 2021 earnings guidance on Tuesday, May, 4th. The company provided earnings per share guidance of 17.500-19.000 for the period, compared to the Thomson Reuters consensus estimate of $18.410. The company issued revenue guidance of $10.45 billion-$10.75 billion, compared to the consensus revenue estimate of $10.57 billion.

What price target have analysts set for BIIB?

30 Wall Street analysts have issued 12 month target prices for Biogen's shares. Their forecasts range from $175.00 to $450.00. On average, they anticipate Biogen's stock price to reach $305.57 in the next twelve months. This suggests a possible upside of 11.6% from the stock's current price.
View analysts' price targets for Biogen
or view top-rated stocks among Wall Street analysts.

Who are Biogen's key executives?

Biogen's management team includes the following people:
  • Mr. Michel Vounatsos, CEO & Director (Age 59, Pay $5.72M) (LinkedIn Profile)
  • Ms. Susan H. Alexander, Exec. VP, Chief Legal Officer & Sec. (Age 64, Pay $1.99M)
  • Dr. Alfred W. Sandrock Jr., Exec. VP of R&D (Age 63, Pay $1.87M)
  • Mr. Chirfi Guindo, Exec. VP of Global Product Strategy & Commercialization (Age 55, Pay $1.32M)
  • Mr. Michael R. McDonnell, Exec. VP & CFO (Age 57)
  • Ms. Robin C. Kramer, Sr. VP & Chief Accounting Officer (Age 55)
  • Mr. Mark J. Hernon, Sr. VP & Chief Information Officer (Age 57)
  • Mr. Michael Hencke, Director of Investor Relations
  • Ms. Natacha Gassenbach, Chief Communication Officer & Head of Corp. Affairs
  • Dr. Ginger Gregory, Exec. VP & Chief HR Officer (Age 53)

What is Michel Vounatsos' approval rating as Biogen's CEO?

186 employees have rated Biogen CEO Michel Vounatsos on Glassdoor.com. Michel Vounatsos has an approval rating of 86% among Biogen's employees.

Who are some of Biogen's key competitors?

What other stocks do shareholders of Biogen own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Biogen investors own include NVIDIA (NVDA), Gilead Sciences (GILD), Netflix (NFLX), Tesla (TSLA), Alibaba Group (BABA), Amgen (AMGN), The Walt Disney (DIS), Intel (INTC), Micron Technology (MU) and The Boeing (BA).

What is Biogen's stock symbol?

Biogen trades on the NASDAQ under the ticker symbol "BIIB."

Who are Biogen's major shareholders?

Biogen's stock is owned by a number of retail and institutional investors. Top institutional investors include LSV Asset Management (0.61%), Swiss National Bank (0.39%), Sumitomo Mitsui Trust Holdings Inc. (0.35%), Parnassus Investments CA (0.21%), Rhumbline Advisers (0.20%) and BNP PARIBAS ASSET MANAGEMENT Holding S.A. (0.19%). Company insiders that own Biogen stock include Alfred Sandrock, Brian S Posner, Michel Vounatsos and Stephen A Sherwin.
View institutional ownership trends for Biogen
.

Which institutional investors are selling Biogen stock?

BIIB stock was sold by a variety of institutional investors in the last quarter, including DnB Asset Management AS, Virginia Retirement Systems ET AL, PGGM Investments, Sumitomo Mitsui Trust Holdings Inc., Robeco Institutional Asset Management B.V., Alberta Investment Management Corp, Exchange Traded Concepts LLC, and M&T Bank Corp.
View insider buying and selling activity for Biogen
or view top insider-selling stocks.

Which institutional investors are buying Biogen stock?

BIIB stock was bought by a variety of institutional investors in the last quarter, including Parnassus Investments CA, State of Michigan Retirement System, Todd Asset Management LLC, BNP PARIBAS ASSET MANAGEMENT Holding S.A., Envestnet Asset Management Inc., Country Trust Bank, Handelsbanken Fonder AB, and Symons Capital Management Inc..
View insider buying and selling activity for Biogen
or or view top insider-buying stocks.

How do I buy shares of Biogen?

Shares of BIIB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Biogen's stock price today?

One share of BIIB stock can currently be purchased for approximately $273.76.

How much money does Biogen make?

Biogen has a market capitalization of $41.22 billion and generates $14.38 billion in revenue each year. The biotechnology company earns $5.89 billion in net income (profit) each year or $33.57 on an earnings per share basis.

How many employees does Biogen have?

Biogen employs 9,100 workers across the globe.

Does Biogen have any subsidiaries?

The following companies are subsidiares of Biogen: AliveGen, Biogen (Argentina) SRL, Biogen (Czech Republic) s.r.o., Biogen (Denmark) A/S, Biogen (Denmark) Manufacturing ApS, Biogen (Denmark) New Manufacturing ApS, Biogen (RTP) Realty LLC, Biogen (Singapore) Pte Ltd, Biogen Australia PTY Ltd, Biogen Austria GmbH, Biogen B.V., Biogen Belgium N.V./S.A., Biogen Biotechnology (Shanghai) Co. Ltd., Biogen Brasil Produtos Farmaceuticos LTDA, Biogen Canada Inc., Biogen Chesapeake LLC, Biogen Chile Spa, Biogen Colombia S.A.S., Biogen Finland OY, Biogen Foundation Inc., Biogen France S.A.S., Biogen GmbH, Biogen Holding APS, Biogen Holding I LLC, Biogen Holding II LLC, Biogen Hungary KFT, Biogen Idec (Ireland) Ltd., Biogen Idec Biotech India Pvt. Ltd., Biogen Idec Hong Kong Limited, Biogen Idec Ltd., Biogen Idec Research Ltd., Biogen Idec Uruguay SA, Biogen International GmbH, Biogen International Holding Limited, Biogen International Neuroscience GmbH, Biogen Italia SRL, Biogen Japan Ltd., Biogen Korea, Biogen Luxembourg Holding SARL, Biogen MA Inc., Biogen Management Services GmbH, Biogen Manufacturing Holding LLC, Biogen Mexico S. DE R.L. DE C.V., Biogen Mexico Servicios S. DE R.L. DE C.V., Biogen NZ Biopharma Ltd., Biogen Netherlands B.V., Biogen New Ventures Inc., Biogen Norway AS, Biogen Pharma farmacevtska in biotehnoloska druzba d.o.o, Biogen Poland Sp. z.o.o, Biogen Portugal Sociedade Farmaceutica Unipessoal Lda., Biogen Realty Corporation, Biogen Realty Limited Partnership, Biogen SRO Inc., Biogen Slovakia s.r.o., Biogen Spain S.L., Biogen Sweden AB, Biogen Swiss Investments GmbH, Biogen Swiss Manufacturing GmbH, Biogen Switzerland AG, Biogen Switzerland Holdings GmbH, Biogen Taiwan Limited, Biogen Therapeutics Inc., Biogen U.S. Corporation, Biogen U.S. Limited Partnership, Biogen U.S. Pacific LLC, Biogen U.S. West Corporation, Conforma Therapeutics, Conforma Therapeutics Corporation, Convergence Pharmaceuticals, Convergence Pharmaceuticals Holdings Ltd., Convergence Pharmaceuticals Ltd., Eidetica Biopharma GmbH, Fumapharm, Karyopharm Therapeutics, Nightstar Europa Limited, Nightstar Inc., Nightstar Limited, Nightstar Therapeutics, Nightstar Therapeutics Limited, Old Convergence Pharmaceuticals Ltd., Panion Ltd., Remedy Pharmaceuticals, Silver Acquisition Co. Ltd., Stromedix, Stromedix Inc., Syntonix Pharmaceuticals, Tungsten Bidco Limited, and Tysabri.

When was Biogen founded?

Biogen was founded in 1978.

What is Biogen's official website?

The official website for Biogen is www.biogen.com.

Where are Biogen's headquarters?

Biogen is headquartered at 225 BINNEY STREET, CAMBRIDGE MA, 02142.

How can I contact Biogen?

Biogen's mailing address is 225 BINNEY STREET, CAMBRIDGE MA, 02142. The biotechnology company can be reached via phone at 617-679-2000 or via email at [email protected]


This page was last updated on 5/7/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.